Our results demonstrate little or no impact of genetic deletion or pharmacologic inhibition of Nlrp3 on NASH in this animal model and call for a more guarded examination of whether NLRP3 targeting would be a viable therapeutic strategy in human NASH. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.